Summit Therapeutics PLC (LON:SUMM, NASDAQ:SMMT) has highlighted new analysis from the group’s Phase Two clinical trial, for its potential treatment for Duchenne muscular dystrophy (DMD).
The company, in a statement, said the new analysis showed a high correlation between reductions in developmental myosin, a biomarker of muscle damage, and reductions in muscle inflammation in patients after 24 weeks of ezutromid treatment.
It added that the findings underpin existing evidence that Summit’s drug, ezutromid, is reducing the severity of DMD.
"The correlation observed between decreases in developmental myosin, a biomarker of muscle damage, and decreases in muscle fibre inflammation, is highly encouraging, and we believe further supports that ezutromid is breaking the DMD disease cycle of muscle damage and repair," said Dr David Roblin, Summit chief medical officer.
“We look forward to reporting the full results of this trial, expected in the third quarter of 2018."
Summit shares climbed 11.5p or 5.97% to trade at 204p.